


At Risk 228 89 25 4

Events 0 103 148 165




N	Male			
At Risk	138	46	14	3
Events	0	76	103	112

Female


At Risk	90	44	12	2
Events	0	27	45	53

	Mala Assessed	matia	Mala In had -E00/ of the day	Famala Assimatam
N	lale, Asymptomat	tic		
At Risk	36	19	7	2
Events	0	13	24	28
M	lale, Symptomation	c and ambulatory		
At Risk	71	21	6	2
Events	0	39	51	54
M	lale, In bed <50%	of the day		
At Risk	29	7	3	0
Events	0	22	26	28
M	lale, In bed > 50%	% of the day		
At Risk	1	0	0	0
Events	0	1	1	1
F	emale, Asympton	natic		
At Risk	27	14	3	0
Events	0	4	8	9
F	emale, Symptom	atic and ambulatory		
At Risk	42	24	9	2
Events	0	12	22	28
F	emale, In bed <5	0% of the day		
At Risk	21	8	2	0
Events	0	11	15	16



At Risk 228 89 25 4

CUM EVENTS 0 103 148 165




	Male			
At Risk	138	46	14	3
CUM EVENTS	0	76	103	112

Fε	m	ıaı	е


•	omaio			
At Risk	90	44	12	2
CUM EVENTS	0	27	45	53

٩				
	Mala Asymptomot	i.a	Mala la had .E00/ af the day	Famala Asympto
I	Male, Asymptoma	tic		
At Risk	36	19	7	2
CUM EVENTS	0	13	24	28
I	Male, Symptomati	c and ambulatory		
At Risk	71	21	6	2
CUM EVENTS	0	39	51	54
1	Male, In bed <50%	% of the day		
At Risk	29	7	3	0
CUM EVENTS	0	22	26	28
1	Male, In bed > 50%	% of the day		
At Risk	1	0	0	0
CUM EVENTS	0	1	1	1
ı	Female, Asymptor	natic		
At Risk	27	14	3	0
CUM EVENTS	0	4	8	9
I	Female, Symptom	atic and ambulato	ry	
At Risk	42	24	9	2
CUM EVENTS	0	12	22	28
ı	Female, In bed <5	0% of the day		
At Risk	21	8	2	0
CUM EVENTS	0	11	15	16



 CUM EVENTS
 228
 89
 25
 4

 N RISK
 0
 103
 148
 165



	Male			
CUM EVENTS	138	46	14	3
N RISK	0	76	103	112
	Female			

	Ciliai
CUM EVENTS	90


N RISK

0		2

44 1227 45

2 53

Yr					
	Mala Asymptomatic		Mala lahad E00/ of the day	Famala Asymata	~~*:C
	Male, Asymptomatic				á
CUM EVENTS	36	19	7	2	
N RISK	0	13	24	28	
	Male, Symptomatic and	d ambulatory			
CUM EVENTS	71	21	6	2	
N RISK	0	39	51	54	
	Male, In bed <50% of the	he day			
CUM EVENTS	29	7	3	0	
N RISK	0	22	26	28	
	Male, In bed > 50% of	the day			
CUM EVENTS	1	0	0	0	
N RISK	0	1	1	1	
	Female, Asymptomatic				
CUM EVENTS	27	14	3	0	
N RISK	0	4	8	9	
	Female, Symptomatic a	and ambulator	ry		
CUM EVENTS	42	24	9	2	
N RISK	0	12	22	28	
	Female, In bed <50% o	of the day			
CUM EVENTS	21	8	2	0	
N RISK	0	11	15	16	




N	Male			
At Risk	138	46	14	3
Events	0	76	103	112


Female

At Risk	90	44	12	2
Events	0	27	45	53

	Mala Assessed	matia	Mala In had -E00/ of the day	Famala Assimatam
N	lale, Asymptomat	tic		
At Risk	36	19	7	2
Events	0	13	24	28
M	lale, Symptomation	c and ambulatory		
At Risk	71	21	6	2
Events	0	39	51	54
M	lale, In bed <50%	of the day		
At Risk	29	7	3	0
Events	0	22	26	28
M	lale, In bed > 50%	% of the day		
At Risk	1	0	0	0
Events	0	1	1	1
F	emale, Asympton	natic		
At Risk	27	14	3	0
Events	0	4	8	9
F	emale, Symptom	atic and ambulatory		
At Risk	42	24	9	2
Events	0	12	22	28
F	emale, In bed <5	0% of the day		
At Risk	21	8	2	0
Events	0	11	15	16





At Risk 228 90 26 5
Events 0 103 148 165



At Risk 227 93 30 6

Events 0 102 147 218







Chemotherapy Treatment — Drug A — Drug B

	Drug A					
At Risk	98	98	95	84	62	0
Events	0	0	2	7	17	24
C	Drug B					

At Risk	102	102	96	76	56	0
Events	0	0	4	17	26	33

Cumulative	0	5	10 Months to De	15 ath/Censor	20	25
Cn		Chemotherapy Treatm	ant Grada		g A, II — Drug A, III g B, II — Drug B, III	
	Drug A,	I				
At Risk	35	35	35	31	23	0
Events	0	0	0	4	7	9
	Drug B,	I				
At Risk	33	33	33	29	24	0
Events	0	0	0	3	5	9
	Drug A,	II				
At Risk	32	32	31	28	24	0
Events	0	0	1	2	3	5
	Drug B,	II				
At Risk	36	36	33	24	18	0
Events	0	0	2	8	12	12
	Drug A,	III				
At Risk	31	31	30	27	17	0
Events	0	0	1	1	7	10
	Drug B,	III				
At Risk	33	33	31	25	16	0
Events	0	0	2	6	9	12






Chemotherapy Treatment — Drug A — Drug B

I	Drug A					
At Risk	98	98	95	84	62	0
CUM EVENTS	0	0	2	7	17	24

ſ	Orug B					
At Risk	102	102	96	76	56	0
CUM EVENTS	0	0	4	17	26	33

Cumulative	0	5	10 Months to D	15 eath/Censor	20	25
Cum	Ch	emotherapy Treatmo	ent, Grade	- Drug A, I — Dr - Drug B, I — Dr		
	Drug A, I					
At Risk	35	35	35	31	23	0
CUM EVENTS	0	0	0	4	7	9
	Drug B, I					
At Risk	33	33	33	29	24	0
CUM EVENTS	0	0	0	3	5	9
	Drug A, II					
At Risk	32	32	31	28	24	0
CUM EVENTS	0	0	1	2	3	5
	Drug B, II					
At Risk	36	36	33	24	18	0
CUM EVENTS	0	0	2	8	12	12
	Drug A, II	I				
At Risk	31	31	30	27	17	0
CUM EVENTS	0	0	1	1	7	10
	Drug B, II	I				
At Risk	33	33	31	25	16	0
CUM EVENTS	0	0	2	6	9	12




Chemotherapy Treatment — Drug A — Drug B


	Drug A					
At Risk	98	98	95	84	62	0
Events	0	0	2	7	17	24
C	Drug B					

At Risk	102	102	96	76	56	0
Events	0	0	4	17	26	33

Cumulative	0	5	10 Months to De	15 ath/Censor	20	25
Cn		Chemotherapy Treatm	ant Grada		g A, II — Drug A, III g B, II — Drug B, III	
	Drug A,	I				
At Risk	35	35	35	31	23	0
Events	0	0	0	4	7	9
	Drug B,	I				
At Risk	33	33	33	29	24	0
Events	0	0	0	3	5	9
	Drug A,	II				
At Risk	32	32	31	28	24	0
Events	0	0	1	2	3	5
	Drug B,	II				
At Risk	36	36	33	24	18	0
Events	0	0	2	8	12	12
	Drug A,	III				
At Risk	31	31	30	27	17	0
Events	0	0	1	1	7	10
	Drug B,	III				
At Risk	33	33	31	25	16	0
Events	0	0	2	6	9	12



Events 0 0 6 24 43 57



At Risk 200 200 193 164 122 0

Events 0 0 6 24 43 57